• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Clarivate Plc

    10/23/23 4:13:25 PM ET
    $CLVT
    EDP Services
    Technology
    Get the next $CLVT alert in real time by email
    SC 13D 1 d572525dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No.  )*

     

     

    Clarivate Plc

    (Name of Issuer)

    Ordinary shares, par value €0.20 per share

    (Title of Class of Securities)

    None

    (CUSIP Number)

    Scott Miller

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, NY 10004

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 12, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G21810109

     

     1   

     NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Giovanni Agnelli B.V.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS* (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

        7   

     SOLE VOTING POWER

     

     42,554,288

        8  

     SHARED VOTING POWER

     

     0

        9  

     SOLE DISPOSITIVE POWER

     

     42,554,288

       10  

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     42,554,288

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     6.29%*

    14  

     TYPE OF REPORTING PERSON* (see instructions)

     

     HC, CO

     

    * 

    This calculation is based on 676,234,313 ordinary shares, no par value (the “Shares”), outstanding as of August 4, 2023, as reported in the Issuer’s Form 10-Q for the quarterly period ended June 30, 2023 (the “Form 10-Q”) which the Issuer filed on August 7, 2023.

     

    Page 2 of 14


    CUSIP No. G21810109

     

     1   

     NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Exor N.V.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS* (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

        7   

     SOLE VOTING POWER

     

     42,554,288

        8  

     SHARED VOTING POWER

     

     0

        9  

     SOLE DISPOSITIVE POWER

     

     42,554,288

       10  

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     42,554,288

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     6.29%*

    14  

     TYPE OF REPORTING PERSON* (see instructions)

     

     HC, CO

     

    * 

    This calculation is based on 676,234,313 Shares outstanding as of August 4, 2023, as reported in the Form 10-Q which the Issuer filed on August 7, 2023.

     

    Page 3 of 14


    CUSIP No. G21810109

     

     1   

     NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Exor Nederland N.V.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS* (see instructions)

     

     WC

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     The Netherlands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

     

        7   

     SOLE VOTING POWER

     

     42,554,288

        8  

     SHARED VOTING POWER

     

     0

        9  

     SOLE DISPOSITIVE POWER

     

     42,554,288

       10  

     SHARED DISPOSITIVE POWER

     

     0

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     42,554,288

    12  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     6.29%*

    14  

     TYPE OF REPORTING PERSON* (see instructions)

     

     HC, CO

     

    * 

    This calculation is based on 676,234,313 Shares outstanding as of August 4, 2023, as reported in the Form 10-Q which the Issuer filed on August 7, 2023.

     

    Page 4 of 14


    CUSIP No. G21810109

     

    Item 1. Security and Issuer.

    Name of Issuer:

    This Schedule 13D relates to the ordinary shares, no par value (the “Shares”), of Clarivate Plc (“Clarivate” or the “Issuer”). The address of the principal executive offices of the Issuer is 70 St. Mary Axe., London EC3A 8BE, United Kingdom.

    Item 2. Identity and Background.

    The information set forth in Items 3, 4, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 2.

     

    (a)

    Name of Person Filing

    This Schedule 13D is being filed jointly by (1) Giovanni Agnelli B.V. (“G.A.”), (2) Exor N.V. (“Exor”) and (3) Exor Nederland N.V. (“Exor Nederland”) and together with G.A. and Exor, the (“Reporting Persons”, and individually referred to herein as a “Reporting Person”). The joint filing agreement of the Reporting Persons is attached as Exhibit 99.1 to this Schedule 13D.

    Exor Nederland is a wholly-owned subsidiary of Exor, which in turn is controlled by G.A.

     

    (b)

    Address of Principal Business Office or, if none, Residence

    The principal business office of the Reporting Persons is: c/o Exor N.V. Gustav Mahlerplein 25 Amsterdam, 1082 MS The Netherlands

     

    (c)

    Principal Business

    G.A. is a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) grouping the descendants of Senator of Giovanni Agnelli, the founder of Fiat. The main business objective of G.A. is to preserve unity and continuity of the Agnelli family’s controlling equity interest in Exor. The name, business address, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) and citizenship of each executive officer and director of G.A. each person controlling G.A. and each executive officer and director of any corporation or other person in control of G.A. are set forth in Schedule A attached hereto.

    Exor and Exor Nederland are each Dutch public limited liability companies (naamloze vennootschap), and each is an investment company that focuses its business on long-term investments in global companies in diversified sectors, mainly in Europe and the United States. The name, business address, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) and citizenship of each executive officer and director of Exor and Exor Nederland, each person controlling Exor and Exor Nederland and each executive officer and director of any corporation or other person in control of Exor and Exor Nederland are set forth in Schedule A attached hereto.

     

    (d)-(e)

    During the last five years, none of the Reporting Persons have been (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws.

     

    Page 5 of 14


    CUSIP No. G21810109

     

    (f)

    Citizenship

    Giovanni Agnelli B.V. – the Netherlands

    Exor N.V. – the Netherlands

    Exor Nederland N.V. – the Netherlands

    Item 3. Source and Amount of Funds or Other Consideration.

    The information set forth in Items 4, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 3.

    The Shares purchased by the Reporting Persons were purchased using investment capital of the Reporting Persons. The aggregate purchase price for the 42,554,288 Shares held by the Reporting Persons is approximately $410,551,348.

    See also the information set forth in Item 4 and Item 6 of this Schedule 13D.

    Item 4. Purpose of Transaction.

    The information set forth in Items 3, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4.

    The Reporting Persons have invested in the Issuer as part of a diversified portfolio of investments across a range of industries and in order to increase their exposure to the information analytics sector.

    Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, may, at any time and from time to time, review, reconsider and change their position and/or change their purpose and/or develop such plans and, in connection therewith, may seek to influence management or the Board of Clarivate with respect to the business and affairs of Clarivate and may from time to time consider pursuing or proposing such matters with advisors, Clarivate or other persons.

    Accordingly, the Reporting Persons reserve the right to develop, modify or change their plans as they deem appropriate. For example, the Reporting Persons may, at any time and from time to time, (1) acquire additional securities of Clarivate in open market or privately negotiated transactions or pursuant to the exercise of warrants, stock options or convertible or exchangeable securities; (2) dispose of such securities; (3) enter into privately negotiated derivative transactions with institutional counterparties either to increase its economic exposure to Clarivate or to hedge the market risk of some or all of its positions in securities of Clarivate; and/or (4) continue to hold such securities for investment purposes. Any such transactions may be effected at any time and from time to time. In reaching any determination as to its future course of action, the Reporting Persons may take into consideration various factors, such as Clarivate’s business and prospects, other developments concerning Clarivate, other business opportunities available to the Reporting Persons, and general economic and stock market conditions, including, but not limited to, the trading prices of the Shares of Clarivate.

    Representatives of the Reporting Persons may from time to time participate in discussion with one another as well as with management of Clarivate, Clarivate’s other shareholders and/or other relevant parties, including other companies that operate in the information analytics sector or other markets in which Clarivate conducts its businesses, in each case relating to matters that may include Clarivate’s strategic plans, business, financial condition, operations and capital structure. The Reporting Persons may engage with any of the parties listed above in discussions that may include one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D. As a result of these activities, the Reporting Persons may suggest, or take a position with respect to, potential changes in the operations, management or capital structure of Clarivate as a means of enhancing shareholder value and the return on its investment in Clarivate. Such suggestions or positions may relate to one or more of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D under Rule 13d-1(a), including, without limitation, Clarivate’s business, results of operations, strategic direction and alternatives, management, Board of Directors and management composition, environmental, social and governance considerations, capital structure and capital and resource allocation.

     

    Page 6 of 14


    CUSIP No. G21810109

     

    Item 5.

    Interest in Securities of the Issuer.

    Item 3 is hereby incorporated by reference in this Item.

     

    (a)

    Rows (11) and (13) of the cover pages to this Schedule 13D are incorporated by reference herein. Mr. A. von Furstenberg, a director of G.A., holds 100,000 shares in Clarivate acquired with personal funds and over which he has sole voting and dispositive power.

     

    (b)

    Rows (7) through (10) of the cover pages to this Schedule 13D are hereby incorporated by reference.

     

    (c)

    The information set forth in Items 3 and 4 of this Schedule 13D is incorporated by reference herein. The transactions in the class of securities reported on in this Schedule 13D that were effected during the past 60 days by or on behalf of the Reporting Persons are set forth in Schedule B and incorporated herein by reference. Other than those transactions, there were no other such transactions by the Reporting Persons that were effected during the past 60 days.

     

    (d)

    Neither the Reporting Persons nor, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities indicated in this Item 5.

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

    The information set forth in Items 3 and 4 of this Schedule 13D is incorporated by reference in its entity into this Item 6.

     

    (a)

    The Reporting Persons previously entered into cash-settled forward agreements with unaffiliated third party financial institutions, which have been terminated. The cash settled forward agreements did not afford the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership of any shares of Common Stock that may have been referenced in the forward contracts or ordinary shares or other securities or financial instruments that may be held from time to time in connection with forward agreement.

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit
    Number

      

    Description of Exhibits

    99.1    Joint Filing Agreement (filed herewith)

     

    Page 7 of 14


    CUSIP No. G21810109

     

    SIGNATURE

    After reasonable inquiry and to the best of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: October 23, 2023     GIOVANNI AGNELLI B.V.
        By:   /s/ Guido De Boer
        Name:   Guido De Boer
        Title:   Authorized Signatory
        EXOR N.V.
        By:   /s/ Guido De Boer
        Name:   Guido De Boer
        Title:   Authorized Signatory
        EXOR NEDERLAND N.V.
        By:   /s/ Guido De Boer
        Name:   Guido De Boer
        Title:   Authorized Signatory

     

    Page 8 of 14


    CUSIP No. G21810109

     

    SCHEDULE A

    Giovanni Agnelli B.V. (“G.A.”)

    Set forth below are the names, business address, present principal occupation or employment of each board member of G.A. Unless otherwise indicated, the business address of each person listed below is c/o Giovanni Agnelli B.V., Gustav Mahlerplein 25, 1082 MS Amsterdam, The Netherlands.

     

    Name and Position with G.A.

      

    Principal Employment, Employer and Business Address

      

    Citizenship

    Jeroen Preller

    Chairman and Board Member

       Partner NautaDutilh, Weena 800, 3014 DA Rotterdam, the Netherlands.    Dutch citizen

    Andrea Agnelli

    Board Member

      

    Executive Chairman Lamse S.p.A., Piazza CLN 255, 10123 Turin, Italy;

     

    Member of the Advisory Board BlueGem Capital Partners LLP, Eagle House 5th Floor, 108 - 110 Jermyn Street, London, SW1Y 6EE, UK;

     

    President Fondazione del Piemonte per l’Oncologia, Strada Provinciale 142 - KM 3.95, 10060 Candiolo TO, Italy.

       Italian citizen

    John Brouwer

    Board Member

      

    Of Counsel at Allen & Overy LLP, Apollolaan 15, 1077 AB Amsterdam, the Netherlands;

     

    Judge at the Tax Chamber of the Court of North Holland, the Netherlands.

       Dutch citizen

    Niccolò Camerana

    Board Member

       Principal at Stellantis Ventures B.V., Taurusavenue 1, 2132 LS Hoofddorp, the Netherlands    Italian citizen

    Benedetto Della Chiesa

    Board Member

      

    Private entrepreneur;

     

    Board Member and Vice-President of investment vehicle Argo 3, promoted by Ulixes Capital Partners S.r.l., Via di Torre Argentina 21, 00186 Roma, Italy.

       Italian citizen

    Luca Ferrero de Gubernatis Ventigmiglia

    Board Member

       Self-employed.    Italian citizen

    Alexandre von Furstenberg

    Board Member

       Chief Investment Officer of Ranger Global Advisors, LLC, 14 Beverly Park, Beverly Hills, CA 90212, USA.    US citizen

    Filippo Scognamiglio

    Board Member

      

    Managing Director & Partner Boston Consulting Group, 10 Hudson Yards, New York, NY 10001, USA.

     

    Board member of The Boston Consulting Group, Inc., Boston, USA

       US citizen

     

    Page 9 of 14


    CUSIP No. G21810109

     

    Exor N.V. (“Exor”)

    Set forth below are the names, business address, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) of the chief executive officer and each director of Exor. Unless otherwise indicated, the business address of each person listed below is c/o Exor N.V., Gustav Mahlerplein 25, 1082 MS Amsterdam, The Netherlands.

     

    Name and Position with Exor

      

    Principal Employment, Employer and Business Address

      

    Citizenship

    John Elkann

    Chief Executive Officer

      

    Chairman Stellantis N.V., Taurusavenue 1, 2132 LS Hoofddorp, the Netherlands;

     

    Chairman Ferrari N.V., Via Abetone Inferiore 4, 41053 Maranello, Italy;

     

    Chairman GEDI Gruppo Editoriale S.p.A., Via Ernesto Lugaro 15, 10126 Turin, Italy;

     

    Chairman Fondazione Giovanni Agnelli;

     

    Member of the Board of Directors Pinacoteca Giovanni e Marella Agnelli, Via Nizza n. 230/103, 10126 Turin, Italy;

     

    Member of the Board of Directors Institut Mérieux, 17, rue Bourgelat, 69002 Lyon, France.

       Italian citizen

    Nitin Nohria

    Chairman and Senior Non-Executive Director

      

    Distinguished Service University Professor at Harvard Business School, Boston, MA 02163, USA;

     

    Chairman Thrive Capital, NYC, New York, USA;

     

    Director Anheuser-Busch InBev, Grand Place 1, 1000 Brussels, Belgium;

     

    Member Board of Trustees Bridgespan Group, 2 Copley Place, 7th Floor, Suite 3700B, Boston, MA 02116, USA;

     

    Chairman Rakuten Medical, 11080 Roselle Street, San Diego, CA 92121, USA;

     

    Director Massachusetts General Brigham, Boston, USA;

       US citizen

    Melissa Bethell

    Non-Executive Director

      

    Senior Advisor Atairos, 17 Duke of York Street, London SW1Y 6LB, UK;

     

    Non-Executive Director Tesco Plc, Tesco House, Shire Park, Kestrel Way, Welwyn Garden City, Hertfordshire AL7 1GA, UK;

     

    Non-Executive Director Diageo Plc, 16 Great Marlborough Street London W1F 7HS, UK.

       British citizen

     

    Page 10 of 14


    CUSIP No. G21810109

     

    Marc Bolland

    Non-Executive Director

      

    Chairman Europe Blackstone Group International Partners LLP, 40, Berkeley Square, London WU SAL, UK;

     

    Non-Executive Director, The Coca-Cola Company, 1 Coca Cola Plz NW, Atlanta, GA 30313, USA;

     

    Vice-President Unicef UK, 1 Westfield Avenue, London E20 1HZ, UK;

     

    Deputy Chairman of the Trustee Board of the Royal Collection Trust, York House, St. James’s Palace, London, England, SW1A 1BQ, UK;

     

    Chairman of the Royal Collection Enterprises, York House, St. James’s Palace, London, SW1A 1BQ, UK.

       Dutch citizen

    Tiberto Brandolini d’Adda

    Non-Executive Director

       Independent member of the Board of Directors YAFA S.p.A., Corso Vittorio Emanuele II 72 Torino, Torino, 10121 Italy.    Italian citizen

    Laurence Debroux

    Non-Executive Director

      

    Member of the Board of Directors Novo Nordisk A/S, Novo Allé, 2880 Bagsvaerd, Denmark;

     

    Non-Executive Director Kite Insights, The Conduit Club, 6 Langley Street, London, England WC2H 9JA, UK;

     

    Member of the Supervisory Board of Randstad N.V., Diemermere 25, 1112 TC Diemen, the Netherlands.

       French citizen

    Sandra Dembeck

    Non-Executive Director

       Chief Financial Officer of Zalando SE, Valeska-Gert-Straße 5, 10243 Berlin, Germany    German citizen

    Axel Dumas

    Non-Executive Director

       Chief Executive Officer Hermès International, 24, rue du Faubourg Saint-Honoré 75008 Paris.    French citizen

    Ginevra Elkann

    Non-Executive Director

      

    President Pinacoteca Giovanni e Marella Agnelli, Via Nizza n. 230/103, 10126 Turin, Italy;

     

    President Asmara Films S.r.l., Via Giuseppe Sacconi 4/b, 00196 Rome, Italy;

     

    Member of the Advisory Board Christie’s, 8 King Street, London SWlY 6QT, UK;

     

    Board member Fondation Cartier, 261, Boulevard Raspail—75014 Paris, France;

     

    Member of the Board of Trustees American Academy in Rome, Via Angelo Masina 5, 00153 Rome, Italy;

     

    Member of the Advisory Board UCCA, 798 Art District, No. 4 Jiuxianqiao Road, Chaoyang District, Beijing 100015, China;

     

    Director Christian Louboutin SAS, 9, Rue Jean Jacques Rousseau, Paris, 75001 France.

       Italian citizen

     

    Page 11 of 14


    CUSIP No. G21810109

     

    Alessandro Nasi

    Non-Executive Director

      

    Chairman Comau S.p.A., Via Rivalta 30, 10095 Grugliasco, Italy;

     

    Chairman Iveco Defence Vehicles S.p.A., Via Alessandro Volta, 6-39100 Bolzano, Italy;

     

    Chairman Astra Veicoli Industriali S.p.A., Via Caorsana 79, 29122 Piacenza, Italy;

     

    Director CNH Industrial N.V., 25 St. James’s Street, London, SW1A 1HA, UK;

     

    Director Iveco Group N.V., Via Puglia n. 35, Turin, Italy;

     

    Member of the Advisory Board Lego Brand Group, Aastvej 1, 7190 Billund, Denmark;

     

    Board member Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy;

     

    Member of the Strategic Advisory Board of 3 Boomerang Capital, 382 Greenwich Avenue—Suite One, Greenwich, CT 06830, USA;

     

    Director GVS S.p.A., Via Roma, 50, 40069 Zona Industriale BO, Italy.

       Italian citizen

    Exor Nederland N.V. (“Exor Nederland”)

    Set forth below are the names, business address, present principal occupation or employment (and the name, principal business and address of any corporation or other organization in which such employment is conducted) of the chief executive officer and each director of Exor Nederland. Unless otherwise indicated, the business address of each person listed below is c/o Exor N.V., Gustav Mahlerplein 25, 1082 MS Amsterdam, The Netherlands.

     

    Name and Position with Exor Nederland

      

    Principal Employment, Employer and Business Address

      

    Citizenship

    Jacob Buit

    Board Member

       Retired    Dutch citizen

    Florence Hinnen

    Board Member

       General Counsel, Exor N.V.    Dutch citizen

    Guido De Boer

    Board Member

       Chief Financial Officer, Exor N.V.    Dutch citizen

    Alina Solomon

    Board Member

       Chief Administrative Officer, Exor N.V.    Romanian citizen

     

    Page 12 of 14


    CUSIP No. G21810109

     

    Schedule B

    Transactions by the Reporting Persons in the shares of the Issuer During the Past 60 Days

     

    Date

       Buy/Sell    Number of Ordinary
    Shares
         Price Per Share ($)  

    10-Oct-23

       BUY      465,194      $ 6.7317  

    11-Oct-23

       BUY      731,528      $ 6.8581  

    12-Oct-23

       BUY      432,149      $ 6.7470  

    13-Oct-23

       BUY      304,243      $ 6.7597  

    16-Oct-23

       BUY      7,221,922      $ 7.1403  

    17-Oct-23

       BUY      103,334      $ 6.7900  

    18-Oct-23

       BUY      42,962      $ 6.9983  

    19-Oct-23

       BUY      365,517      $ 6.7664  

    20-Oct-23

       BUY      415,419      $ 6.7329  

     

    Page 13 of 14

    Get the next $CLVT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLVT

    DatePrice TargetRatingAnalyst
    11/6/2024Outperform → Mkt Perform
    William Blair
    12/15/2023$8.00Equal Weight → Underweight
    Wells Fargo
    10/16/2023$10.00 → $8.50Hold → Buy
    Jefferies
    9/8/2023$8.00 → $7.00Equal Weight → Underweight
    Barclays
    8/25/2023$9.00 → $8.00Outperform → Sector Perform
    RBC Capital Mkts
    8/7/2023$10.00 → $6.00Neutral → Underperform
    BofA Securities
    8/4/2023$15.00 → $8.00Overweight → Equal Weight
    Wells Fargo
    6/13/2023$11.00Outperform
    Oppenheimer
    More analyst ratings

    $CLVT
    SEC Filings

    See more
    • Clarivate Plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - CLARIVATE PLC (0001764046) (Filer)

      6/2/25 8:45:15 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate Plc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - CLARIVATE PLC (0001764046) (Filer)

      5/19/25 4:49:39 PM ET
      $CLVT
      EDP Services
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by Clarivate Plc

      SCHEDULE 13G/A - CLARIVATE PLC (0001764046) (Subject)

      5/14/25 4:29:43 PM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    Leadership Updates

    Live Leadership Updates

    See more
    • Clarivate Appoints Henry Levy as President, Life Sciences & Healthcare

      Concludes the appointments for business leaders of its three market segments LONDON, April 26, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, announced today that it has appointed Henry Levy as President, Life Sciences & Healthcare, effective May 1, 2023. Henry joins from Veeva Systems, a global leader in cloud software for the life sciences industry, where he most recently served as President, Global R&D and Quality, with responsibility for driving sales across the segment. Jonathan Gear,

      4/26/23 7:00:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate Names Bar Veinstein as President, Academia & Government

      Appointing the second of three business leaders for its newly created market segments LONDON, April 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Bar Veinstein will join the company as President, Academia & Government, effective April 24, 2023. Bar joins from Taranis, an AI-powered crop intelligence provider, where he was Chief Executive Officer focusing on driving business growth, improving customer satisfaction and accelerating the company's artificial intelligence (AI) strategy. He previously spent 11 years with the Ex Libris Group, now part of Clarivate, and under his leader

      4/19/23 7:00:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

      Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.

      3/23/23 4:30:00 PM ET
      $CLVT
      $CNTA
      EDP Services
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLVT
    Financials

    Live finance-specific insights

    See more
    • Clarivate to Report Second Quarter 2025 Results on July 30, 2025

      LONDON, July 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the second quarter 2025 before the market opens on Wednesday, July 30, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Wednesday, July 30, 2025 to review the results. The webcast is open to all interest

      7/8/25 7:30:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate Reports First Quarter 2025 Results

      — Accelerated recurring organic revenue growth — — Reaffirmed 2025 Outlook — — Repurchased $50 million ordinary shares — LONDON, April 29, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2025. Total revenues for the first quarter of 2025 was $593.7 million, compared to total revenues of $621.2 million for the first quarter of 2024. Organic revenues for the first quarter of 2025 increased 0.3%, compared to the first quarter of 202

      4/29/25 6:00:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate to Report First Quarter 2025 Results on April 29, 2025

      LONDON, April 2, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the first quarter 2025 before the market opens on Tuesday, April 29, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Tuesday, April 29, 2025 to review the results. The webcast is open to all interested

      4/2/25 8:05:00 AM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clarivate to Report Second Quarter 2025 Results on July 30, 2025

      LONDON, July 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, announced today it will report its financial results for the second quarter 2025 before the market opens on Wednesday, July 30, 2025. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com. The Company will host a conference call and webcast at 9:00 AM Eastern Time on Wednesday, July 30, 2025 to review the results. The webcast is open to all interest

      7/8/25 7:30:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate Unveils the 2025 Journal Citation Reports

      50th Anniversary Year Sees Strengthened Focus on Research Integrity LONDON, June 18, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2025 update to the Journal Citation Reports (JCR). This is the 50th anniversary of the industry-leading annual reports, which provide a comprehensive overview of the world's leading and trusted academic journals, offering academic institutions, researchers, and publishers the ability to gauge journals' trustworthiness and impact. Only journals that have met the rigorous

      6/18/25 3:00:00 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate Partners with American Library Association to Advocate for U.S. Libraries

      LONDON, June 9, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a new milestone in its decades-long partnership with the American Library Association (ALA). Clarivate will be the first sponsor of the ALA Public Supporter Program, which engages the public in supporting libraries and library professionals.   The ALA is the largest library association in the world. It advocates for libraries, library workers, and everyone they serve, from small, rural libraries to the largest library systems in the country.

      6/9/25 3:00:00 AM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Clarivate downgraded by William Blair

      William Blair downgraded Clarivate from Outperform to Mkt Perform

      11/6/24 8:22:43 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Clarivate from Equal Weight to Underweight and set a new price target of $8.00

      12/15/23 8:04:33 AM ET
      $CLVT
      EDP Services
      Technology
    • Clarivate upgraded by Jefferies with a new price target

      Jefferies upgraded Clarivate from Hold to Buy and set a new price target of $8.50 from $10.00 previously

      10/16/23 9:11:50 AM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bomba Jane L Okun was granted 6,686 units of Ordinary Shares and covered exercise/tax liability with 306 units of Ordinary Shares, increasing direct ownership by 3% to 213,670 units (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      7/2/25 4:27:41 PM ET
      $CLVT
      EDP Services
      Technology
    • Director Snyder Andrew Miles was granted 11,918 units of Ordinary Shares and covered exercise/tax liability with 527 units of Ordinary Shares, increasing direct ownership by 7% to 164,489 units (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      7/2/25 4:27:30 PM ET
      $CLVT
      EDP Services
      Technology
    • President, IP Samson James Gordon sold $453,000 worth of Ordinary Shares (100,000 units at $4.53), decreasing direct ownership by 7% to 1,271,103 units (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      7/2/25 4:27:20 PM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Snyder Andrew Miles bought $989,024 worth of Ordinary Shares (237,176 units at $4.17) (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      3/18/25 4:56:10 PM ET
      $CLVT
      EDP Services
      Technology
    • Director Bomba Jane L Okun bought $200,492 worth of Ordinary Shares (49,750 units at $4.03) (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      3/14/25 4:14:29 PM ET
      $CLVT
      EDP Services
      Technology
    • Director Pritchett Wendell E. bought $100,114 worth of Ordinary Shares (22,857 units at $4.38), increasing direct ownership by 47% to 71,835 units (SEC Form 4)

      4 - CLARIVATE PLC (0001764046) (Issuer)

      3/5/25 4:17:24 PM ET
      $CLVT
      EDP Services
      Technology

    $CLVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clarivate Plc

      SC 13G/A - CLARIVATE PLC (0001764046) (Subject)

      12/5/24 10:02:09 AM ET
      $CLVT
      EDP Services
      Technology
    • SEC Form SC 13G filed by Clarivate Plc

      SC 13G - CLARIVATE PLC (0001764046) (Subject)

      11/13/24 4:18:30 PM ET
      $CLVT
      EDP Services
      Technology
    • SEC Form SC 13D/A filed by Clarivate Plc (Amendment)

      SC 13D/A - CLARIVATE PLC (0001764046) (Subject)

      3/4/24 9:01:44 AM ET
      $CLVT
      EDP Services
      Technology